Botanical extracts and compounds from Schinus plants and methods of use

US12083132B1 · US · B1

Patent metadata
FieldValue
Publication numberUS-12083132-B1
Application numberUS-202318121280-A
CountryUS
Kind codeB1
Filing dateMar 14, 2023
Priority dateJul 10, 2015
Publication dateSep 10, 2024
Grant dateSep 10, 2024

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

This disclosure relates to extracts from the Anacardiaceae (cashew plant family) and compositions comprising compounds contained therein. In certain embodiments, the extracts are derived from the fruit of a Schinus plant. In certain embodiments, the disclosure relates to methods of treating or preventing bacterial infections, acne, and other related uses.

First claim

Opening claim text (preview).

The invention claimed is: 1. A pharmaceutical formulation comprising: (a) a therapeutically effective amount of a compound of the formula below or a salt thereof, and (b) a pharmaceutically acceptable excipient. 2. The pharmaceutical formulation of claim 1 , wherein the formulation is a particle, bead, tablet, capsule, or pill. 3. The pharmaceutical formulation of claim 1 , wherein the formulation is a lotion, liquid, or gel. 4. The pharmaceutical formulation of claim 1 , wherein the formulation further comprises an additional antibiotic. 5. The pharmaceutical formulation of claim 1 , wherein the formulation further comprises a steroid. 6. The pharmaceutical formulation of claim 1 , wherein the formulation further comprises an anti-inflammatory agent. 7. A method of treating or preventing a bacterial infection in a subject comprising administering to the subject an effective amount of a pharmaceutical formulation comprising: (a) a therapeutically effective amount of a compound of the formula below or a salt thereof, and (b) a pharmaceutically acceptable excipient. 8. The method of claim 7 , wherein the subject has an abscess, furuncle, cellulitis, folliculitis, atopic dermatitis, psoriasis, impetigo, septic arthritis, brain abscess, burn wound, venous ulcer, diabetic foot ulcer, surgical wound, carbuncle, or meningitis. 9. The method of claim 7 , wherein the subject has bacteremia, pneumonia, staphylococcal food poisoning, necrotizing pneumonia, necrotizing fasciitis, scaled skin syndrome, post-operation bacterial infection, medical device bacterial infection, bacterial infection of the skin, soft tissue bacterial infection, or toxic shock syndrome. 10. The method of claim 7 , wherein the bacterial infection is a toxin-mediated bacterial infection. 11. The method of claim 10 , wherein the toxin-mediated bacterial infection is a Staphylococcus -mediated bacterial infection. 12. The method of claim 7 , wherein administering comprises topical administration of the formulation. 13. The method of claim 7 , further comprising administering to the subject an additional antibiotic. 14. The method of claim 13 , wherein the formulation further comprises an additional antibiotic. 15. The method of claim 7 , further comprising administering to the subject a steroid. 16. The method of claim 15 , wherein the formulation further comprises a steroid. 17. The method of claim 7 , further comprising administering to the subject an anti-inflammatory agent. 18. The method of claim 17 , wherein the formulation further comprises an anti-inflammatory agent.

Assignees

Inventors

Classifications

  • A61K31/575Primary

    substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol · CPC title

  • Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak · CPC title

  • Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00) · CPC title

  • Antibacterial agents · CPC title

  • Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US12083132B1 cover?
This disclosure relates to extracts from the Anacardiaceae (cashew plant family) and compositions comprising compounds contained therein. In certain embodiments, the extracts are derived from the fruit of a Schinus plant. In certain embodiments, the disclosure relates to methods of treating or preventing bacterial infections, acne, and other related uses.
Who is the assignee on this patent?
Univ Emory
What technology area does this patent fall under?
Primary CPC classification A61K31/575. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).